Round Table Services LLC Maintains Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Round Table Services LLC maintained its stake in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) during the second quarter, Holdings Channel reports. The institutional investor owned 129,500 shares of the biopharmaceutical company’s stock at the end of the second quarter. Round Table Services LLC’s holdings in Inovio Pharmaceuticals were worth $1,015,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in Inovio Pharmaceuticals during the fourth quarter valued at approximately $559,000. Vident Investment Advisory LLC raised its stake in Inovio Pharmaceuticals by 67.5% in the fourth quarter. Vident Investment Advisory LLC now owns 106,147 shares of the biopharmaceutical company’s stock valued at $737,000 after buying an additional 42,764 shares during the period. Wells Fargo & Company MN raised its stake in Inovio Pharmaceuticals by 28.9% in the first quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock valued at $825,000 after buying an additional 27,898 shares during the period. Stoneridge Investment Partners LLC raised its stake in Inovio Pharmaceuticals by 0.8% in the first quarter. Stoneridge Investment Partners LLC now owns 254,449 shares of the biopharmaceutical company’s stock valued at $1,684,000 after buying an additional 2,073 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Inovio Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after buying an additional 11,765 shares during the period. Institutional investors own 27.74% of the company’s stock.

Inovio Pharmaceuticals, Inc. (NASDAQ INO) traded down 9.59% during midday trading on Thursday, hitting $6.13. The stock had a trading volume of 9,242,921 shares. The stock has a 50-day moving average price of $7.88 and a 200 day moving average price of $6.96. Inovio Pharmaceuticals, Inc. has a 12-month low of $5.83 and a 12-month high of $11.00. The firm’s market cap is $457.46 million.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The business had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $5.83 million. During the same period last year, the company posted ($0.11) EPS. The company’s revenue was up 28.4% on a year-over-year basis. On average, equities analysts anticipate that Inovio Pharmaceuticals, Inc. will post ($1.10) earnings per share for the current fiscal year.

WARNING: “Round Table Services LLC Maintains Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)” was posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://baseballnewssource.com/markets/round-table-services-llc-maintains-position-in-inovio-pharmaceuticals-inc-nasdaqino/1237250.html.

Several equities research analysts have commented on INO shares. Zacks Investment Research lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, April 17th. Stifel Nicolaus reiterated a “buy” rating and set a $11.00 price objective on shares of Inovio Pharmaceuticals in a research note on Tuesday, April 25th. BNP Paribas reiterated a “neutral” rating and set a $39.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Jefferies Group LLC reiterated a “neutral” rating and set a $38.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Finally, Nomura reiterated a “buy” rating and set a $40.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $19.90.

In other news, Director David B. Weiner sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total transaction of $64,000.00. Following the completion of the transaction, the director now directly owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 10.60% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Want to see what other hedge funds are holding INO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inovio Pharmaceuticals, Inc. (NASDAQ:INO).

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base


Leave a Reply

 
© 2006-2017 BBNS.